Work

244: Fludarabine-based non-myeloablative stem cell transplantation in a patient with sickle cell disease and renal failure

Year: 2007

Type: article

Abstract: End-organ damage is common in adult patients with Sickle Cell Disease (SCD), therefore an effective non-myeloablative approach to allogeneic stem cell transplantation (SCT) would be ideal. Fludarabine is a component of most non-myeloablative conditioning regimens. Since 40% of the active metabolite, 2-fluoro-ara-A (F-Ara-A), is cleared by the kidneys, use in patients with renal insufficiency or renal failure is hazardous. We report the outcome of two adult SCD patients who underwent non-myeloablative SCT from their HLA-identical matched siblings on an NHLBI-sponsored clinical trial.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2006.12.249